Skip to main content

Advertisement

Log in

Recent trends in the morbidity and mortality in patients with familial adenomatous polyposis: a retrospective single institutional study in Japan

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

This study aimed to assess current trends in morbidity and mortality among patients with familial adenomatous polyposis (FAP). These data can be used for optimal surveillance and management of such patients.

Methods

Data (November 2001 and April 2020) of genetically confirmed patients with FAP (n = 87) and their first-degree relatives with FAP phenotype (n = 20) were extracted from the Saitama Medical Center database. Standardized mortality ratio (SMR) and standardized incidence ratio (SIR) were estimated using indirect method.

Results

Overall, 46 men and 61 women were included; the median age at FAP diagnosis was 28.0 years for both. The SMR for all causes of death was 47.7 (95% confidence interval [CI] 19.1–98.2) in women and 26.5 (95% CI 9.73–57.8) in men. The SIR for colorectal cancer (CRC) was 860 (95% CI 518–1340) in women and 357 (95% CI 178–639) in men. The SMR for CRC was 455 (95% CI 93.7–1330) in women and 301 (95% CI 62.0–879) in men. Thirteen patients died during the observation period, and CRC was the leading cause of death (46%). Other causes of death included desmoid tumor (n = 2), small intestinal cancer (n = 2), ovarian cancer (n = 1), duodenal cancer (n = 1), and sepsis (n = 1).

Conclusions

The mortality ratio, estimated using SMR, remained high. CRC was the leading cause of death, whereas almost half of the causes of deaths were extra-colonic tumors. Life-long management of extra-colonic diseases may improve the prognosis in these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Komatsu I (1968) A clinical genetic study on multiple intestinal polyposis and allied conditions. Jinrui Idengaku Zasshi 12:246–297

    CAS  PubMed  Google Scholar 

  2. Utsunomiya J, Iwama T, Ichikawa T et al (1973) Present status of familial polyposis of the colon in Japan-results of the nationwide survey (1961–1972). Nihon Shokakibyo Gakkai Zasshi 70:707–726

    CAS  PubMed  Google Scholar 

  3. Iwama T, Tamura K, Morita T et al (2004) A clinical overview of familial adenomatous polyposis derived from the database of the Polyposis Registry of Japan. Int J Clin Oncol 9:308–316

    Article  Google Scholar 

  4. Weren RD, Ligtenberg MJ, Kets CM et al (2015) A germline homozygous mutation in the base-excision repair gene NTHL1 causes adenomatous polyposis and colorectal cancer. Nat Genet 47:668–671

    Article  CAS  Google Scholar 

  5. Short E, Sampson J (2019) The role of inherited genetic variants in colorectal polyposis syndromes. Adv Genet 103:183–217

    Article  CAS  Google Scholar 

  6. Carr S, Kasi A (2020) Familial adenomatous polyposis. Treasure Island (FL), StatPearls Publishing LLC, StatPearls

    Google Scholar 

  7. Jasperson KW, Patel SG, Ahnen DJ (1993) APC-Associated polyposis conditions, in GeneReviews(®). Seattle, USA

    Google Scholar 

  8. Utsunomiya J, Iwama T, Imajo M et al (1980) Total colectomy, mucosal proctectomy, and ileoanal anastomosis. Dis Colon Rectum 23:459–466

    Article  CAS  Google Scholar 

  9. Breslow NE, Day NE (1987) Statistical methods in cancer research. Volume II–The design and analysis of cohort studies. IARC Sci Publ 82:1–406

    Google Scholar 

  10. Death and population data by age of 2012, Japan. Available via DIALOG. https://www.mhlw.go.jp/toukei/saikin/hw/jinkou/geppo/nengai13/index.html. Accessed Oct 2020

  11. Cancer Registry and Statistics, Cancer Information Service, National Cancer Center, Japan (Monitoring of Cancer Incidence in Japan (MCIJ)). Available via DIALOG. https://ganjoho.jp/reg_stat/statistics/brochure/backnumber/2019_jp.html. Accessed Oct 2020

  12. Statistics, J. e-Stat Statistics of Japan. Available via DIALOG. https://www.e-stat.go.jp/. Accessed Oct 2020

  13. Schoenberg BS (1983) Caluculating confidence intervals for rates and ratios- Simplified method utilizing tabular values based on the poisson distribution. Neuroepidemiology 2:257–265

    Article  Google Scholar 

  14. Iwama T, Mishima Y, Utsunomiya J (1993) The impact of familial adenomatous polyposis on the tumorigenesis and mortality at the several organs. Its rational treatment. Ann Surg 217:101–108

    Article  CAS  Google Scholar 

  15. Galle TS, Juel K, Bülow S (1999) Causes of death in familial adenomatous polyposis. Scand J Gastroenterol 34:808–812

    Article  CAS  Google Scholar 

  16. Bülow S (2003) Results of national registration of familial adenomatous polyposis. Gut 52:742–746

    Article  Google Scholar 

  17. Tomita N, Ishida H, Tanakaya K et al (2021) Japanese society for cancer of the colon and rectum (JSCCR) guidelines 2020 for the clinical practice of hereditary colorectal cancer. Int J Clin Oncol. https://doi.org/10.1007/s10147-021-01881-4

    Article  PubMed  PubMed Central  Google Scholar 

  18. Chugh R, Wathen JK, Patel SR et al (2010) Efficacy of imatinib in aggressive fibromatosis: results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. Clin Cancer Res 16:4884–4891

    Article  CAS  Google Scholar 

  19. Mir O, Cropet C, Toulmonde M et al (2016) Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial. Lancet Oncol 17:632–641

    Article  CAS  Google Scholar 

  20. Penel N, Le Cesne A, Bui BN et al (2011) Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. Ann Oncol 22:452–457

    Article  CAS  Google Scholar 

  21. Kasper B, Gruenwald V, Reichardt P et al (2017) Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG). Eur J Cancer 76:60–67

    Article  CAS  Google Scholar 

  22. Jo JC, Hong YS, Kim KP et al (2014) A prospective multicenter phase II study of sunitinib in patients with advanced aggressive fibromatosis. Invest New Drugs 32:369–376

    Article  CAS  Google Scholar 

  23. Gounder MM, Mahoney MR, Van Tine BA et al (2018) Sorafenib for advanced and refractory desmoid tumors. N Engl J Med 379:2417–2428

    Article  CAS  Google Scholar 

  24. Watanabe Y, Ishida H, Baba H et al (2017) Pancreas-sparing total duodenectomy for Spigelman stage IV duodenal polyposis associated with familial adenomatous polyposis: experience of 10 cases at a single institution. Fam Cancer 16:91–98

    Article  CAS  Google Scholar 

  25. Kumagai Y, Higashi M, Muramatsu S et al (2020) Endocytoscopic observation of non-ampullary mucosal duodenal cancer. Case Rep Gastroenterol 14:156–164

    Article  Google Scholar 

  26. Yamaguchi T, Ishida H, Ueno H et al (2016) Upper gastrointestinal tumours in Japanese familial adenomatous polyposis patients. Jpn J Clin Oncol 46:310–315

    Article  Google Scholar 

  27. Sada H, Hinoi T, Ueno H et al (2019) Prevalence of and risk factors for thyroid carcinoma in patients with familial adenomatous polyposis: results of a multicenter study in Japan and a systematic review. Surg Today 49:72–81

    Article  Google Scholar 

  28. Yamada A, Watabe H, Iwama T et al (2014) The prevalence of small intestinal polyps in patients with familial adenomatous polyposis: a prospective capsule endoscopy study. Fam Cancer 13:23–28

    Article  Google Scholar 

  29. Nugent KP, Spigelman AD, Phillips RK (1993) Life expectancy after colectomy and ileorectal anastomosis for familial adenomatous polyposis. Dis Colon Rectum 36:1059–1062

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We would like to thank Aya Saito and Fumiyo Fukui for their help during genetic testing. We would like to thank Editage (www.editage.com) for English language editing.

Funding

The authors did not received support from any organization for the submitted work.

Author information

Authors and Affiliations

Authors

Contributions

HI designed and conceptualized this study. KA, OS, KC, NK, HS, AY, NC, and KI collected data. YM analyzed the data. T Ito, OS, KC, KA, SH, NC, AY, KI, T Iwama, and HI provided medical care for the patients. YM, TI, and HI interpreted the data and drafted the manuscript. HE and YO performed genetic analysis and interpretation. All authors have read and approved the final manuscript.

Corresponding author

Correspondence to Yoshiko Mori.

Ethics declarations

Conflict of interest

The authors have no conflict of interest to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 20 KB)

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mori, Y., Amano, K., Chikatani, K. et al. Recent trends in the morbidity and mortality in patients with familial adenomatous polyposis: a retrospective single institutional study in Japan. Int J Clin Oncol 27, 1034–1042 (2022). https://doi.org/10.1007/s10147-022-02146-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-022-02146-4

Keywords

Navigation